Adenovir Pharma´s patent applications relating to its novel “antiviral compound” (APD-209) for treatment of the serious and very contagious eye infection, epidemic keratoconjunctivitis (EKC), have been approved in several countries. Most recently it was granted in Russia by the Federal Service for Intellectual Property.

The company’s base patent, which relates to its technology platform, is already granted in several important markets such as EU, US, Japan, China, etc.

To read  more about Adenovir Pharma, visit

For more information, please contact:
Björn Dellgren, CEO/project leader, Adenovir Pharma AB, or
+46 (0)707 455 005.